Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.

ABSTRACT:

Background

Advanced liver fibrosis in cases of metabolic dysfunction-associated steatotic liver disease (MASLD) leads to cirrhosis and hepatocellular carcinoma. The current gold standard for liver fibrosis is invasive liver biopsy. Therefore, a less invasive biomarker that accurately reflects the stage of liver fibrosis is highly desirable.

Methods

This study enrolled 269 patients with liver biopsy-proven MASLD. Patients were divided into three groups (F0/1 (n = 41/85), F2 (n = 47), and F3/4 (n = 72/24)) according to fibrosis stage. We performed serum N-glycomics and identified glycan biomarker for fibrosis stage. Moreover, we explored the carrier proteins and developed a sandwich ELISA to measure N-glycosylation changes of carrier protein.

Results

Comprehensive N-gly

SUBMITTER: Hanamatsu H 

PROVIDER: S-EPMC11922979 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature